Exicure Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Andy Yoo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	less than a year

Recent management updates

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25

CEO

Andy Yoo (45 yo)

less than a year

Tenure

Mr. Andy Yoo is CEO & President of Exicure, Inc. from December 17, 2024 and has been its Director since November 21, 2024 and was its Chief Restructuring Officer from November 21, 2024 to December 17, 2024...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andy Yoo	CEO, President & Director	less than a year	no data	no data
Seung Baik	CFO, Secretary & Director	less than a year	no data	no data
Joshua Miller	Chief Accounting Officer	1.7yrs	no data	0.0073% $ 2.1k
Jiyoung Hwang	Chief Strategic Officer & Director	less than a year	no data	no data

0.08yrs

Average Tenure

46yo

Average Age

Experienced Management: XCUR's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Andy Yoo	CEO, President & Director	less than a year	no data	no data
Seung Baik	CFO, Secretary & Director	less than a year	no data	no data
Jiyoung Hwang	Chief Strategic Officer & Director	1.9yrs	no data	no data
Michael Hodges	Member of Advisory Board	no data	no data	no data
Amy Paller	Member of Advisory Board	no data	no data	no data
Henry Paulson	Member of Advisory Board	5.1yrs	no data	no data
Paul Kang	Director	1.9yrs	no data	no data
Dongho Lee	Independent Director	1.4yrs	no data	no data
Sangwook Song	Director	less than a year	no data	no data
Minwoo Kang	Director	less than a year	no data	no data
Ho John	Director	less than a year	no data	no data
Chang Choi	Director	less than a year	no data	no data

0.2yrs

Average Tenure

47yo

Average Age

Experienced Board: XCUR's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/12 13:42
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Exicure, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
null null	BMO Capital Markets Equity Research
Keay Nakae	Chardan Capital Markets, LLC
Yatin Suneja	Guggenheim Securities, LLC

Exicure Management

Management criteria checks 0/4

Key information

Recent management updates

Exicure, Inc. Announces Board Changes

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure, Inc., Annual General Meeting, Jun 28, 2024

No independent directors

Exicure, Inc. Appoints Minhee Eom to the Board

Recent updates

New major risk - Shareholder dilution

Exicure, Inc. Announces Board Changes

Exicure Request for Subsequent Extension to Nasdaq Hearings Panel Till December 17

New minor risk - Shareholder dilution

Nasdaq Hearings Panel Grants Exicure Extension for Continued Listing on The Nasdaq Capital Market, Compliance Required by November 14, 2024

Exicure Regains Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Exicure Announces 1-for-5 Reverse Stock Split to Regain Compliance with Nasdaq’s Listing Rules

High number of new and inexperienced directors

Exicure, Inc. Appoints Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics

Exicure Receives Positive Listing Determination from Nasdaq

Exicure Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

Exicure, Inc., Annual General Meeting, Jun 28, 2024

Exicure, Inc. Receives Nasdaq Notice of A Delisting Determination

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. announced delayed annual 10-K filing

New minor risk - Financial data availability

No independent directors

Exicure Receives Non-Compliance Notice From Nasdaq

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure, Inc. announced delayed 10-Q filing

Exicure, Inc. Appoints Minhee Eom to the Board

Exicure Receives Non-Compliance Notice From Nasdaq

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure, Inc. Announces Executive Changes

Less than half of directors are independent

Exicure Notifies Nasdaq Regarding Continued to be Not in Compliance with Rule 5605(c)(2)(A)

Exicure Receives Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

CBI USA Inc Sends a Letter to Exicure Inc

Exicure, Inc. announced delayed 10-Q filing

No independent directors

Exicure, Inc. Announces Resignation of Jeffrey L. Cleland from the Board of Directors, Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

Exicure Receives Notice from Nasdaq Regarding No Longer in Compliance with Nasdaq's Independent Director and Audit Committee Requirements

Exicure, Inc. Announces Resignation of Jiyoung Hwang from the Board of Directors

Exicure, Inc. Announces Executive Changes

Exicure, Inc. Contemplates Bankruptcy

Exicure, Inc. announced that it expects to receive $5.44 million in funding from CBI Inc.

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Exicure Receives Noncompliance Notice from Nasdaq

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exicure Q2 GAAP loss per share narrows, revenue up

Exicure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Exicure regains compliance with Nasdaq's minimum bid price requirement

Exicure Announces Receipt of Nasdaq Notice of Non-Compliance

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Exicure, Inc. announced that it expects to receive $5.040289 million in funding from CBI USA, Inc, Abingworth LLP

High number of new and inexperienced directors

Exicure, Inc., Annual General Meeting, May 27, 2022

Exicure, Inc. Announces Executive, Board and Committee Changes

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Exicure, Inc. Investors

Exicure Receives A Letter from the Staff Nasdaq Stock Market

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Exicure, Inc

Price target decreased to US$6.75

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Consensus revenue estimates increase to US$12.9m

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.049 loss in 2Q 2020)

Consensus revenue estimates increase to US$22.1m

Price target decreased to US$9.00

Exicure, Inc.(NasdaqCM:XCUR) dropped from Russell Microcap Value Index

Consensus revenue estimates fall to US$5.77m

Price target decreased to US$9.60

Exicure, Inc. Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients with Unmet Medical Needs

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2020)

Co-Founder & Director Chad Mirkin has left the company

Consensus revenue estimates increase to US$8.91m

Full year 2020 earnings released: US$0.28 loss per share (vs US$0.46 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Exicure, Inc. Announces Spherical Nucleic Acid Technology Shows Promising Results in Phase 0 Trial in Patients with Glioblastoma

Exicure, Inc. Announces David R. Walt Did Not Stand for Re Election